glp-1 drugs and fatty liver Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic disease (NAFLD): A systematic review - Lv - 2020 - Endocrinology, Diabetes & Metabolism SGLT-2 inhibitors and GLP-1 receptor

GLP-1R regulation of food intake The reduction in body weight induced by GLP-1R agonists is largely attributed to a reduction in food intake

In clinical studies, liraglutide and semaglutide both led to an average 0.3-point drop in A1c in prediabetic participants (after 56 weeks for liraglutide 5 and 68 weeks for semaglutide 6 )a small but meaningful shift for people whose blood sugar is creeping upward toward the diabetes threshold

Pharmacokinetics Half-life : ~7 days supports once-weekly dosing Peak plasma concentration : Reached in 13 days post-injection Metabolism : Proteolytic cleavage and -oxidation of fatty acid side chain Excretion : Primarily via urine and feces

HR, 0.91 [95% CI, 0.57-1.45]

Diabetes Care 40 , 161163 (2017)